-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $280

Benzinga·10/30/2026 15:07:09
RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $345 to $280.